← Eichor
Study identifier: NCT03563417 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO

Condition: Ischemic Heart Disease · Chronic Total Occlusion of Coronary Artery  ·  Sponsor: Aarhus University Hospital Skejby

PhaseNA
Planned participants1560
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Study design Prospective randomized open labeled multicenter study Hypotheses 1. In asymptomatic patients with ≥ 10% of myocardial ischemia: PCI (Percutaneous Coronary Intervention) with latest generation of drug eluting stents is superior to optimal medical therapy in terms of relative reduction in MACCE (Major Adverse Cardiovascular and Cerebrovascular events). 2. In symptomatic patients with ≥ 5% of myocardial ischemia: PCI with latest generation of drug eluting stents is superior to optimal medical therapy (OMT) in terms of improved life quality measured as an increase of SAQ (Self Assessment Questionnaire) score of 8 points after 6 months. Inclusion Criteria * CTO in native coronary artery * Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging. * Age ≥18 yrs. * Able to provide written Informed consent and willing to comply with the specified follow-up contacts * Target artery ≥ 2.5 mm Prior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into: Cohort A: Asymptomatic (CCS \< 2 and SAQ QoL \> 60) patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO Cohort B: Symptomatic patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO Cohort C: patients enrolled but not randomized in cohort A or B Exclusion criteria (for both cohort A and B) * NSTEMI or STEMI within …

This description comes directly from the study's public registry record.

Talk to the study team

Evald Christiansen, MD PhD  ·  +45 78452028  ·  evald.christiansen@dadlnet.dk

Emil N Holck, MD  ·  +45 31419472  ·  eh@clin.au.dk

Always discuss trial participation with your own doctor first.

Locations (27)

Aarhus University HospitalAarhus N, DenmarkRecruiting
RigshospitaletCopenhagen, DenmarkRecruiting
Gentofte HospitalHellerup, DenmarkRecruiting
Odense University HospitalOdense, DenmarkRecruiting
Zealand University HospitalRoskilde, DenmarkRecruiting
North-Estonia Medical CentreTallinn, EstoniaRecruiting
Helsinki University Central HospitalHelsinki, FinlandActive Not Recruiting
Kuopio University HospitalKuopio, FinlandActive Not Recruiting
Heart Hospital TampereTampere, FinlandRecruiting
Turku University HospitalTurku, FinlandRecruiting
Clinique Louis PasteurEssey-lès-Nancy, FranceActive Not Recruiting
Cardiovascular Institute, Groupe Hospitalier MutualisteGrenoble, FranceRecruiting

+ 15 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03563417